Baxter International looks to sales and margin growth after it spins out its biopharmaceutical arm as Baxalta, likely augmented with acquisitions.
Baxter (NYSE:BAX) said it plans to boost its sales and margin growth after the planned July 1 spinout of its biopharmaceutical division as Baxalta.
from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1F1xVdu
Cap comentari:
Publica un comentari a l'entrada